These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16329453)

  • 1. [Natural remedies and hormone preparations--potential risk for breast cancer patients. A study surveys the use of agents which possibly counteract with the treatment].
    Malekzadeh F; Rose C; Ingvar C; Jernström H
    Lakartidningen; 2005 Oct 31-Nov 6; 102(44):3226-8, 3230-1. PubMed ID: 16329453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Natural remedies--self care at your own risk! Danger of unknown adverse effects and interactions with "common" medications].
    Peterson C
    Lakartidningen; 2005 Oct 31-Nov 6; 102(44):3200-1. PubMed ID: 16329448
    [No Abstract]   [Full Text] [Related]  

  • 3. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
    Spicer J; Ellis P
    Cancer Lett; 2007 Apr; 248(2):165-74. PubMed ID: 16919870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current adjuvant endocrine treatment of breast cancer].
    Dedes KJ; Gabriel N; Fink D
    Gynakol Geburtshilfliche Rundsch; 2008; 48(3):130-7. PubMed ID: 18566529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
    Poole R; Paridaens R
    Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant endocrine therapy in breast cancer.
    Beresford MJ; Ravichandran D; Makris A
    Cancer Treat Rev; 2007 Feb; 33(1):48-57. PubMed ID: 17134840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M; Rody A
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatase inhibitors in breast cancer: an overview.
    Altundag K; Ibrahim NK
    Oncologist; 2006 Jun; 11(6):553-62. PubMed ID: 16794235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
    Wheler J; Johnson M; Seidman A
    Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
    Gligorov J; Pritchard K; Goss P
    Breast; 2007 Dec; 16 Suppl 3():S1-9. PubMed ID: 18061455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
    Dodwell D; Williamson D
    Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemoprevention for breast cancers].
    Lanng C
    Ugeskr Laeger; 2007 Sep; 169(36):2975-6. PubMed ID: 17953872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors].
    Ohtake T; Yasuda M; Watanabe K; Ito T; Ito J; Miyamoto K; Yoshida S; Abe N; Ishigame T; Ishii M; Kimijima I; Takenoshita S
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1459-63. PubMed ID: 19755813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
    Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
    J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of premenopausal metastatic breast cancer treated with goserelin plus aromatase inhibitor as second-line endocrine therapy].
    Baba S; Oji Y; Teramoto M; Kawabata K; Saito A
    Gan To Kagaku Ryoho; 2009 Nov; 36(11):1905-6. PubMed ID: 19920398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?
    Trinkaus M; Chin S; Wolfman W; Simmons C; Clemons M
    Oncologist; 2008 Mar; 13(3):222-31. PubMed ID: 18378532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to endocrine therapy for breast cancer.
    Chlebowski RT; Geller ML
    Oncology; 2006; 71(1-2):1-9. PubMed ID: 17344666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.